Argos raises $25M for Phase III trial of kidney cancer drug

04/24/2012 | BioWorld Online (free registration)

Argos Therapeutics secured $25 million in a financing round to support a late-stage trial of AGS-003, a dendritic cell immunotherapy candidate, in patients with newly diagnosed metastatic renal cell carcinoma. The study will start this summer. AGS-003 has fast-track status from the FDA.

View Full Article in:

BioWorld Online (free registration)

Published in Brief: